ArticleHuman vaccines & immunotherapeutics2025
The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endemic coronaviruses (eCoVs) cause the common cold in humans, particularly affecting children, the elderly, and individuals with comorbidities, who are prone to infection-related hospitalization. While vaccination remains the most effective preventative strategy against infections, vaccines against eCoVs are not available. This study investigates the association between SARS-CoV-2 and influenza vaccination and reduced eCoV-related mortality risk. Data from Brazil's nationwide hospital database included patients PCR-positive for one of four eCoV strains, with known admission and clinical endpoint dates, and either vaccinated against SARS-CoV-2 and/or influenza or unvaccinated. Cox regression assessed the vaccines' effectiveness in reducing 90-day in-hospital all-cause mortality. Of 4,283,391 registered cases, 2,636 were eCoV infections. Influenza vaccination, primarily inactivated formulations, was associated with a 39% lower mortality hazard. Conversely, SARS-CoV-2 vaccination showed no significant mortality reduction. This disparity may stem from SARS-CoV-2 vaccines targeting the spike protein, which differs markedly from eCoV spike proteins, limiting cross-protection. In contrast, inactivated influenza vaccines may reduce eCoV mortality through trained innate immunity and cross-reactive cellular responses, offering broader protective effects against these viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.